TLR7 and cancer: Furthermore, we proposed that incorporating a TLR7/8 agonist into both nanocarriers could further amplify the immune response at the cancer site, as previously demonstrated by us.[7] The rationale behind this combination is supported by preliminary transcriptomic analyses, suggesting that simultaneous application of these two platforms leads to an enhanced expression of key genes involved in antigen processing, presentation, and T cell activation.